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One of the oldest questions in acute stroke management, and perhaps the most 
challenging since it has yet to be solved after more than half a century of published 
research, is how to manage high blood pressure (BP). The problem might be summed 
up as:  
“To treat, or not to treat: that is the question: 
Whether ‘tis nobler in the mind to suffer 
The slings and arrows of outrageous pressure, 
Or to take drugs against a sea of blood, 
And by opposing end them? To live: to walk;’ 
(With apologies to Shakespeare – Hamlet Act III, Scene I). 
To treat, or not to treat, high BP was debated more than 30 years ago in 1985 1-3 and 
yet there is no definitive answer here in 2018. Part of the debate is driven by 
opposing arguments based on epidemiology and pathophysiology, and part by the 
failure of every large trial to provide a definitive answer. There is considerable 
evidence that high BP is associated independently with a poor outcome after 
ischaemic stroke whether defined by early recurrence or death, or late death and 
dependency.4, 5 Similarly, high BP is related to haematoma expansion 6 and functional 
outcome after intracerebral haemorrhage (ICH).7 A straight-forward conclusion of this 
epidemiological evidence is that high BP should be lowered. In contrast, 
pathophysiological concerns are based on the presence of dysfunctional cerebral 
autoregulation during acute stroke, and so lowering BP will reduce tissue perfusion, 
increase lesion size, and thereby worsen outcome.8 
 
There are many causes of high BP in acute stroke, including prior hypertension, acute 
neuroendocrine stimulation (via the renin-angiotensin-aldosterone, sympathetic 
autonomic nervous, and corticotrophin-cortisol systems), the Cushing reflex (due to 
raised intracranial pressure), and stress associated with admission to hospital and 
concurrent pain (e.g. due to urinary retention).9 These factors offer multiple targets 
for treatment. 
 
The principle of uncertainty (or clinical equipoise) has driven the completion of a 
number of medium and large sized trials in acute ischaemic, haemorrhagic, or mixed 
stroke (Table 1).  
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Although varying considerably in design, the trials each compared active or intensive 
lowering of BP with no or guideline-based lowering. Whilst some smaller trials 
involving a few hundreds of patients were negative (i.e. treatment worsened 
outcome: BEST, Bridgers, INWEST 14, 15, 20), larger trials (involving a thousand or more 
patients) have all been neutral (SCAST, INTERACT-2, CATIS, ENOS, ATACH-2 12, 13, 16, 
21, 22). For the sake of this review, SCAST can be considered to be negative since the 
presence of two primary outcomes meant that the shift in mRS in a negative direction 
(p=0.048) just missed statistical significance at p<0.025.21 Equally, INTERACT-2 can 
be considered to be positive since although it was neutral on its primary dichotomous 
analysis of the mRS (p=0.06), intensive BP-lowering was associated with a positive 
shift analysis (p=0.04) and improved quality of life (p=0.002).12 
 
Without definitive positive trials, a conclusion at this stage could be that the 
epidemiological observations are epiphenomena and do not predict the effect of 
intervention, as has been seen in other areas of medicine such as vitamin 
supplementation,25 and therefore that BP does not need to be lowered. However, an 
alternative hypothesis is that lowering BP may be a useful marker of efficacy but 
effects on outcome depend on which sort of stroke is being treated, how and when BP 
is lowered, and what other effects the treatment has. This review examines the 
hypothesis that it is how and when BP is first lowered, and in what stroke type, that is 
important rather than lowering BP per se. The review uses the results of published 
medium and large-sized trials, as summarised in two Cochrane Collaboration 
systematic reviews 26, 27 along with more recent studies. Where relevant, reference to 
small mechanistic or pharmacodynamic trials is also made. It does not address 
whether antihypertensive drugs taken before stroke should be continued or stopped 
temporarily,28 or whether and how antihypertensive agents should be taken long term 
for secondary prevention.29  
 
Antihypertensive therapy is rich with multiple evidence-based drug classes, and seven 
classes have been tested in acute stroke (Tables 2, 3). There are no medium-to-large 
sized trials involving centrally acting drugs, endothelin antagonists, or renin inhibitors. 
 
 
Antihypertensive drug classes of relevance in acute stroke 
 
Alpha adrenoceptor antagonists (a-AA) 
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Stimulation of alpha1-adrenegric receptors increases smooth muscle contraction 
under catecholamine control. Antagonism of these receptors by drugs such as 
doxazosin and urapidil leads to vasorelaxation. 32.5% of patients in the INTERACT-2 
trial in ICH received an a-AA, typically urapidil (Table 1).12 Treatment improved the 
mRS and the results are compatible with the hypothesis that blocking noradrenaline 
and adrenaline may be beneficial. Nevertheless, the first and smaller INTERACT trial 
had a higher utilisation of a-AA but was neutral.11 The ENCHANTED-BP trial is using a 
similar approach of testing intensity of BP lowering in patients with hyperacute 
ischaemic stroke,19 and interim data suggest a high utilisation of a-AA (personal 
communication: C Anderson, results expected early 2019). 
 
Angiotensin converting enzyme inhibitors (ACE-I) 
Angiotensin converting enzyme converts the inactive hormone angiotensin I to the 
active vasoconstrictor angiotensin II. Hence, ACE-I such as enalapril cause 
vasorelaxation. The large CATIS trial in acute ischaemic stroke reported a neutral 
effect of intravenous enalapril on mRS (Table 1).16 No large trials of ACE-I for acute 
ICH have been reported. 
 
Angiotensin receptor antagonists (ARA) 
The angiotensin II receptor-1 is activated by the vasoconstrictor angiotensin II. 
Antagonism of the receptor with drugs such as candesartan and valsartan leads to 
vasorelaxation. The large SCAST trial assessed oral candesartan, with doses rising 
over the treatment period, in patients with acute ischaemic and haemorrhagic stroke 
(Table 1). Practically, the trial can be considered to be negative,21 with all the harm 
occurring in patients with ICH and a neutral effect in ischaemic stroke.10, 17 The 
medium-sized VENTURE trial of oral valsartan for acute IS was also neutral.18 One 
interpretation is that elevated angiotensin II levels in acute ICH are important and 
their effects should not be blocked. Alternatively or additionally, blockade of the 
angiotensin II AT1 receptor leaves the AT2 receptor exposed, and agonism of this 
leads to inhibition of cell growth and neuronal regeneration.30 The neutral findings of 
CATIS, SCAST and VENTURE suggest that the renin-angiotensin-aldosterone system 
(RAAS) is not a useful target in acute stroke. 
 
Beta adrenoceptor antagonists (ß-RA) 
Stimulation of beta-1-adrenegric receptors increases cardiac muscle contraction 
(inotropic effect) and heart rate (chronotropic effect) under catecholamine control. As 
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a result, antagonism of these receptors by drugs such as atenolol and propranolol 
reduces cardiac output and heart rate. The BEST trial in acute mixed stroke found that 
these agents, when given orally, increased mortality at one month (Table 1).20 
Although BEST was not large and separate results for ICH and ischaemic stroke are 
not published, one interpretation that is plausible biologically is that reducing cardiac 
output in acute stroke is potentially hazardous. 
 
Some drugs have antagonist effects on both alpha and beta receptors, such as 
labetalol (where beta-antagonist effects dominate). Whilst some guidelines 
recommend using this agent in acute stroke,31 there is limited evidence on the effect 
of labetalol on functional outcome after stroke to support this assertion, with just 14% 
of INTERACT-2 treated with labetalol. 
 
Calcium channel blockers (CCB) 
The movement of calcium through L-type channels in cell membranes drives smooth 
muscle contraction. Hence blockade of these channels with dihydopyridine CCBs, such 
as nicardipine and nimodipine, causes vasorelaxation. Numerous trials of CCBs have 
been performed in acute stroke, usually testing nimodipine as a putative 
neuroprotectant. Although nimodipine had no overall effect in ischaemic stroke,32 two 
trials found that high dose intravenous therapy was associated with a worse functional 
outcome.14, 15 The moderately large ATACH-2 trial assessed intravenous nicardipine in 
hyperacute ICH and was neutral leading to the trial being stopped early for futility 
(Table 1).13 Since dihydopyridine CCBs have some antiplatelet activity,33, 34 their use 
in ICH (as recommended in guidelines, Supplementary Table I) might be considered 
questionable. 
 
Diuretics 
Of the multiple types of diuretics, loop diuretics (furosemide) have been used in acute 
stroke. They act by inhibiting the renal luminal Na-K-Cl cotransporter in the thick 
ascending limb of the loop of Henle. 12.4% of patients in the positive INTERACT-2 
trial in ICH received a loop diuretic. A small trial of bendroflumethiazide, a thiazide 
diuretic, found that it had minimal blood pressure effect over the first week of 
treatment in patients with acute stroke.35 
 
Nitric oxide donors (NO donor) 
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NO is a potent endogenous mixed arterial and venous vasodilator and has significant 
hypotensive effects. Vascular levels of NO are low after stroke 36, 37 so it is plausible to 
supplement it. NO may be administered as a nitrate (such as nitroglycerin, NTG, also 
known as glyceryl trinitrate) or spontaneous NO donor (such as sodium nitroprusside, 
SNP). The large ENOS trial of transdermal NTG found that it did not alter mRS 22 
although hyperacute administration within 6 hours was associated with improved 
functional outcome in a pre-defined subgroup (Table 1).23 NO donors (NTG, SNP) were 
used in 27% of patients with ICH in the positive hyper-acute INTERACT-2 trial.12 The 
ongoing RIGHT-2 trial is assessing NTG administered by paramedics before hospital 
admission (with results expected in early 2019). 
 
 
Stroke type 
 
Trials of BP lowering have been performed in ICH alone, ischaemic stroke alone, and 
mixed groups of patients (Table 1). Whilst probable efficacy was seen in the 
INTERACT-2 trial in ICH,12 nicardipine was neutral in ATACH-2,13 and candesartan 
(ARA) appeared to be harmful in the subgroup of SCAST patients with ICH.10 Opposing 
results were also seen in trials of mixed groups of patients; whilst two studies of NTG 
were positive in both stroke types when given early,23, 38 ß-RA were negative in 
BEST.20 
 
 
Timing 
 
The trials varied considerably in their time-window from onset-to-randomisation, this 
ranging from less than 6 to less than 48 hours. The only evidence for benefit was seen 
in those studies where patients were randomised within 6 hours, as seen in 
INTERACT-2, RIGHT and ENOS-early.12, 23, 38 This observation is comparable with the 
time-dependency seen for thrombolysis and thrombectomy in ischaemic stroke,39, 40 
and raises the possibility that at least some effects of NTG may be related to 
reperfusion following vasodilation.41 Trials recruiting beyond 6 hours were all neutral 
(CATIS, ENOS, VENTURE 16, 18, 22) or negative (BEST, INWEST 15, 20). The subgroup of 
patients randomised after 24 hours into the CATIS trial appeared to have less death 
or major disability at 3 months although this was not apparent at 14 days or hospital 
discharge, and so may reflect the play of chance.16 An outlier is the neutral 1000-
14/5/18 
Page 7 of 19 
patient ATACH-2 trial that recruited patients within 4.5 hours of ICH onset and 
lowered BP with intravenous nicardipine; this result may be more related to use of a 
dihydopyridine CCB per se (as already discussed) rather than timing. 
 
 
Trial size 
 
This review largely focusses on medium-to-large trials involving 100s to 1000s of 
participants, and so of comparable sizes to trials of thrombectomy and intravenous 
thrombolysis respectively. Even the largest completed trials involving more than 4000 
participants (CATIS, ENOS) will not have been large enough to detect small but 
potentially clinically worthwhile effect sizes. The ongoing INTERACT-3 trial is more-
then-twice the size of these already-large trials (Table 1). 
 
 
Additional effects of antihypertensive agents 
 
The various antihypertensive drug classes exhibit multiple other (collateral) effects 
(Table 2), some of which might be considered advantageous (such as potential 
neuroprotection) and others a disadvantage (such as reducing cardiac output). 
 
Cerebral blood flow (CBF)/perfusion 
A number of small studies have been performed that assessed CBF or cerebral blood 
flow velocity following administration of an ACE-I, ARA, ß-RA (labetalol), CCB, 
diuretic, or NO donor.46-49 Whilst no difference in CBF was seen in randomised 
controlled trials, an increase in CBF was seen with CCBs in before-after studies. 
However, all these studies were small (median size 24 participants) and tended to be 
of low-medium quality. No CBF studies investigated ß-RA or labetalol. There is an 
urgent need for large high quality randomised trials using modern imaging techniques 
and assessing the effects of antihypertensives on CBF, especially those agents 
recommended in guidelines or that are widely used (labetalol, nicardipine, NTG, 
urapidil). 
 
Cardiac output 
ß-RA such as propranolol and atenolol reduce cardiac output which may then reduce 
CBF, a debateable aim when this is already reduced in the penumbral area of 
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ischaemic stroke and in ischaemic areas around haematoma. This sequence might 
explain increased deaths seen in the BEST trial.20 Exploring the relationship between 
cardiac output and CBF is important since labetalol, which has significant ß-RA 
activity, is recommended in guidelines and is widely used. Verapamil, a 
phenylalkylamine CCB, also has negative inotropic, chronotropic and dromotropic 
effects, but this drug has not been assessed in ischaemic stroke. 
 
Blood pressure variability 
High BP and a number of derivatives, including mean arterial pressure, pulse 
pressure, BP variability, peak systolic BP and rate-pressure product, are each 
associated with early events and late poor outcome in both acute IS 5, 50 and ICH.51 
Although all the antihypertensive drug classes discussed here lower BP (by definition) 
they have varying effects on variability:52 whilst CCBs and non-loop diuretics reduce 
inter-individual variance, ACE, ARA and ß-RA increase variability. Further, these 
differences seen in variability appear to explain, in part, differences seen in the effects 
of these drug classes on stroke.52 NTG, a NO donor, also reduces variability.53 
Whether effects on variability explain the results of acute stroke BP trials remains 
unclear since neutral or negative results were seen with agents that both reduce 
(CCBs) or increase (ACE, ARA and ß-RA) variability. 
 
Neuroprotection 
Several antihypertensive drug classes (ARA, CCB, NO donors) have putative 
neuroprotective properties,32, 42, 45 at least in animal models of stroke. The relevance 
of this is unclear since no large clinical trials of putative neuroprotectants have led to 
their introduction in clinical practice. 
 
Antiplatelet 
Multiple antihypertensive classes (ARA, ß-RA, CCB, spontaneous NO donors such as 
SNP) exhibit antiplatelet activity. Intravenous CCBs are widely used for the 
hyperacute management of high BP after stroke in spite of neutral results in ICH 
(nicardipine in ATACH-2 13) and some negative results in IS (nimodipine in Bridgers, 
INWEST 14, 15). Although there are many hypotheses why INTERACT-2 and ATACH-2 
gave different results in hyper-acute ICH (Supplementary Table II),54 a key potential 
explanation is that the mild antiplatelet effects of dihydopyridine CCBs (which includes 
nicardipine) 33, 34 neutralised its BP effects in ATACH-2. 
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Anti-white cell effects 
Nitric oxide and some NO donors (e.g. SNP but not NTG), ACE-I and ARA, have anti-
white cell activity manifest through reduction of leucocyte migration, adhesion and 
other functions.55-58 In contrast, the effect of other antihypertensive classes on 
leucocyte activity is unclear. Accentuated white cell function occurs soon after stroke 
with neutrophils then monocytes invading the brain; one trial of an anti-leucocyte 
monoclonal in acute IS was negative with increased death and worse functional 
outcome.59 Hence, there is a risk that antihypertensives with anti-leucocyte activity 
might be harmful; pharmacodynamics studies examining white cell function in acute 
stroke are urgently needed. 
 
Inhibition of renin-angiotensin-aldosterone system (RAAS) 
ACE-I, ARA and ß-RA exert some or all of their BP-lowering effect by attenuating the 
RAAS. Although acute stroke is associated with RAAS stimulation, attenuating this 
activity appears unhelpful since trials have found that ACE-I and ARA were neutral in 
IS (CATIS, SCAST 16, 17), ARA was negative in ICH (SCAST 10), and ß-RA were 
negative in mixed stroke.20 
 
Inhibition of the sympathetic autonomic nervous system (SANS) 
Noradrenaline is a key vasoconstrictor and levels are elevated in acute stroke.60 
Hence, blocking its effects will lower BP and might improve cerebral perfusion. No 
large pure a-AA trials have been performed but they are frequently used in China 
(typically with urapidil) and a significant minority of patients took them in the 
INTERACT studies,11, 12 and are on them in the ongoing ENCHANTED trial. 
 
 
The future 
 
The hypothesis presented here is that it is when and how BP is lowered, and in which 
type of stroke, that is important, not whether BP is lowered per se. Further, it is the 
additional effects of antihypertensives that may drive effects on outcome. This 
hypothesis is data driven and depends on the results of completed medium and large-
sized trials. In essence, intervention probably needs to be started within the ultra- 
and hyper-acute phase of stroke (<6 hours) if a beneficial effect is to be seen, and 
efficacy may be localised to one or two classes, a-AA and NO donors. The evidence for 
a-AA is less clear since urapidil was used more in INTERACT, which showed no 
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tendency to an effect on functional outcome, than the positive INTERACT-2 trial. 
Further, these results apply only to ICH. Whilst ENOS was neutral for treatment within 
48 hours, NTG appeared to improve mRS in both IS and ICH if given within 6 hours in 
both ENOS and RIGHT.61 If the observation for a-AA and NTG are true, then 
attenuating sympathetic activity and/or supplementing vascular NO 41 may be key 
mechanisms for facilitating efficacy when lowering BP. 
 
However, the findings are soft and more trials are required, and the ongoing 
ENCHANTED-BP, ICH-ADAPT-2, INTERACT-3, MR-ASAP and RIGHT-2 trials (Table 1) 
will help test these hypotheses. If none of these predictions deliver, then it is possible 
that BP is a bystander in very acute stroke and lowering it is unimportant. New 
studies are required to further assess the effects of the various antihypertensive 
classes on additional mechanisms as listed in Table 2, including parameters such as 
BP variability.62 Imaging studies in IS need to assess effects of BP lowering on CBF, 
collateral circulation, penumbral size, influence of intra and extra-cranial stenosis, and 
interaction with mechanical thrombectomy. Similarly, imaging studies in ICH need to 
assess induction of ischaemia (as is being investigated in ICH-ADAPT-2) and effects 
on haematoma characteristics such as spot sign, oedema, intraventricular 
haemorrhage, and proximal ischaemia. Ongoing and future large trials will need to 
assess the role of lowering BP not just by stroke type, but by severity and aetiology; 
for example, BP lowering may have differential effects in stroke related to small vessel 
disease in comparison with large artery and cardioembolic stroke. Further, future 
trials may need to be much larger (as with the ongoing INTERACT-3 bundle trial, 
Table 1) and so able to detect small but clinically meaningful effect sizes. 
 
In contrast to remaining questions about efficacy within 6 hours, no agents appear to 
be beneficial when given later than 6 hours; worse, some classes appear to be 
hazardous including ARA in ICH, intravenous CCB in ischaemic stroke, and ß-RA in 
either stroke type. Guidelines that recommend the use of labetalol (with predominant 
ß-RA activity) and CCB for lowering BP in acute stroke may need to be revised 
(Supplementary Table I). 
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Table 1. Medium and large randomised controlled trials of blood pressure lowering in acute stroke. Where relevant, subgroups of 
trials are shown in brackets 
 
 Intervention/Class (agent) Size OTR 
(hours) 
Result; comment(s) 
ICH     
(SCAST-ICH 10 ARA (candesartan po) 274 <30 Negative) 
INTERACT 11 Intensity, multiple classes: a-AA (urapidil iv, phentolamine) 63%; 
loop diuretic (furosemide) 35%; NO donor (nitroglycerin) 13% 
404 <6 Neutral 
INTERACT-2 12 Intensity, multiple classes: a-AA (urapidil iv) 32.5%; NO donor 
(nitroglycerin, nitroprusside) 27.0%; CCB (nicardipine) 16.2%; 
combined alpha-AA/ß-RA (labetalol) 14.4%; diuretic (furosemide) 
12.4% 
2794 <6 Neutral; positive on 
ordinal analysis 
ATACH-2 13 CCB (nicardipine iv) 1000 <4.5 Neutral 
INTERACT-3 
bundle 
Intensity, multiple classes (+ glucose and temperature control, and 
reversal of anticoagulation) 
~8621 <6 Ongoing 
ICH-ADAPT-2 Intensity using labetalol, hydralazine, enalapril ~270 <6 Ongoing 
IS     
Bridgers 14 CCB (nimodipine iv) 204 <24 Negative tendency 
INWEST 15 CCB (nimodipine iv)   Negative 
CATIS 16 ACE (enalapril iv) then CCB then diuretic 4071 <24 Neutral 
(SCAST-IS 17 ARA (candesartan po)  <30 Neutral) 
VENTURE 18 ARA (valsartan po) 393 <48 Neutral 
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ENCHANTED-
BP 19 
Intensity (mainly a-AA, urapidil iv)   Ongoing 
Mixed     
BEST 20 ß-RA (atenolol, propranolol po) 302 <48 Negative 
SCAST 21 ARA (candesartan po) 2029 <30 Neutral; negative if 
recurrence co-primary 
ignored 
ENOS 22 NO donor (NTG td) 4096 <48 Neutral 
ENOS-early 23 NO donor (NTG td) 273 <6 Positive) 
RIGHT-2 24 NO donor (NTG td) ~1105 <4 Ongoing 
MR-ASAP NO donor (NTG td) ~1400 <3 Ongoing 
 
ARA: angiotensin receptor antagonist; a-AA: alpha-receptor antagonist; CCB: calcium channel blocker; ICH: intracerebral 
haemorrhage; IS: ischaemic stroke; iv: intravenous; NO: nitric oxide; NTG: nitroglycerin/glyceryl trinitrate; OTR: onset to 
randomisation; td: transdermal 
INTERACT-3: https://clinicaltrials.gov/ct2/show/NCT03209258 
ICH-ADAPT: https://clinicaltrials.gov/ct2/show/NCT02281838 
MR_ASAP: https://www.isrctn.com/ISRCTN99503308 
RIGHT-2: http://right-2.ac.uk 
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Table 2. Characteristics of antihypertensive drug classes on additional mechanisms 
 
Class CBF CO HR BPV NP Plt WBC RAAS SANS Outcome Comments 
a-AA   ()       ICH ? 
IS ? 
Positive early after ICH? 
ENCHANTED-BP 
ACE-I          IS  Neutral after IS. Avoid in ICH? 
ARA     + 
42 
    ICH ? 
IS  
SCAST-ICH: Negative – AT2 receptor effects? 
SCAST-IS, VENTURE 
ß-RA       
43 
   IS  Enhance hypoperfusion? 
CCB  () ()  + 
32 
    IS  
ICH  
Neutral after IS,44 with some negative trials 
Diuretics            Onset slow (thiazide-like) 35 
NO   ()  + 
45 
() ()   ICH ? 
IS ? 
Positive early after IS and ICH? Supplement 
low vascular levels.36, 37 Enhance reperfusion? 
Spontaneous NO donors (e.g. SNP), but not 
nitrates, have antiplatelet activity 46 
 
ACE-I; angiotensin converting enzyme-inhibitors; ARA: angiotensin receptor antagonists; A-AA: alpha-receptor antagonists; BPV: 
blood pressure variability; ß-RA: beta-receptor antagonists; CBF: cerebral blood flow; CCB: calcium channel blockers; CO: cardiac 
output; ICH: intracerebral haemorrhage; IS: ischaemic stroke; NO: nitric oxide donors; Plt: Platelet function; RAAS: renin-
angiotensin-aldosterone system; SANS: sympathetic autonomic nervous system; SNP: sodium nitroprusside; UK: unknown 
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Table 3. Summary of results divided by time from onset-to-treatment, stroke type and class of antihypertensive agent in patients 
with acute stroke 
 
Time Stroke type a-AA NO Diuretic ACE-I ARA CCB ß-RA 
<6 ICH + +? +?   0  
 IS ? +?      
>6 ICH  0   –/0  - 
 IS  0  0 0 - - 
 
Trial results: -: negative; 0: neutral; +: positive; ?: ongoing trial(s) 
a-AA: alpha-receptor antagonist; ACE-I: angiotensin converting enzyme-inhibitors; ARA: angiotensin receptor antagonist; ß-RA: 
beta-receptor antagonist; CCB: calcium channel blocker; NO: nitric oxide donor;  
 
 
